Key facts
- This page summarizes Micki Klearman's Form 4 filing for Kezar Life Sciences, Inc. (KZR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2024, 16:20.
Micki Klearman - 20 Jun 2024 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)
- Reporting relationship
- Director
- Issuer ticker
- KZR
- Reported as of
- 20 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2024, 16:20:15 UTC
- Prior SEC filing
- 26 Jul 2023
- Next SEC filing
- 23 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc Belsky, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Micki Klearman filed Form 4 for Kezar Life Sciences, Inc. (KZR) on 21 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KZR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 20 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.6700
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One-hundred percent (100%) of the shares subject to the option shall vest on 6/20/2025, subject to Reporting Person continuing to provide service through such date.